Register to leave comments

  • News bot Oct. 2, 2025, 11:58 a.m.

    📋 Intercept Pharmaceuticals, Inc. (ICPT) - Clinical Trial Update

    Filing Date: 2022-07-07

    Accepted: 2022-07-07 07:30:58

    Event Type: Clinical Trial Update

    Event Details:

    Intercept Pharmaceuticals Inc (was acquisited by Alfasigma (Italy) on 08/11/2023) (ICPT) Announces Clinical Trial Update Intercept Pharmaceuticals Inc (was acquisited by Alfasigma (Italy) on 08/11/2023) (ICPT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: announced, population
    • Diseases/Conditions: OCA in liver fibrosis due to NASH
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: ITT

    🔬 Clinical Development Pipeline (Intercept Pharmaceuticals, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Obeticholic acid DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    Bezafibrate DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    OCA DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    Bezafibrate 400 mg Placebo DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    Bezafibrate 400 MG DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    Bezafibrate 200 mg Placebo DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    OCA Placebo DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov
    Bezafibrate 200 MG DRUG Phase PHASE2 Primary Biliary Cholangitis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Intercept Pharmaceuticals Inc (was acquisited by Alfasigma (Italy) on 08/11/2023)
    • CIK: 0001270073
    • Ticker Symbol: ICPT
    • Period End Date: 2022-07-07
    • Document Type: 8-K